GT Biopharma Inc (GTBP)

[TPX]

GT Biopharma Inc (OTCMKTS:GTBP) Makes Great Strides In War Against Cancer



The drugs business is very competitive. Firms lack relevance if they do not innovate to avail new products to combat chronic ailments. To that end, GT Biopharma Inc (OTCMKTS:GTBP) commits to continually innovate to fight cancer.

New product trial
In an August 28, 2018 press statement, the biotechnology company announced trial of OXS-1550. The trial incorporates another “multi-billion dollar oncology drug.” The project is a joint initiative with “a major Pharmaceutical Company (the Company).”

According to the statement, Dr. Daniel Vallera will lead the initiative. Per the release, Dr Vallera is Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota.

Commenting on the trial, he said:

“Based on our exciting preliminary in vitro experiments, the initial preclinical work suggests a much greater effect when OXS-1550 is given with this drug. We are very excited about our progress with GT’s OXS-1550 (DT2219) combined with ibrutinib, a potent small molecule Bruton Tyrosine Kinase (BTK) inhibitor which is already an established chemotherapeutic agent. We believe combination therapies like these that kill cancer cells based on entirely different mechanisms are the future of cancer treatment.”

GT Biopharma Inc (OTCMKTS:GTBP) in strategic partnerships
Further, GT Biopharma Inc (OTCMKTS:GTBP) announced advanced stages in the concept behind Natural Killer cell (NK) hypothesis. As part of the efforts to materialize the research, GT Biopharma is working with “colleagues at the Masonic Center.” The partnership aims to facilitate transitioning of “TriKE and TetraKE NK cell-engager platforms” into clinical development. Specifically, GT Biopharma wants the partnership to help on the regulatory requirements.

We have found a handful of Hemp Oil companies that qualify to be all organic and grown in the U.S.A. Here is one of the best all organic CBD oil products on the market. It’s by Greenleaf Farms, I believe you can get up to 30% by visiting them today!

The company’s Chairman and CEO is optimistic regarding the mainstream interest in the NK cell field. In his words, he says:

“I believe that the NK cell field, much like the T-cell field did some years ago, is about to explode onto the scene with rapid advances in both the science and the clinical development spheres. I also believe that GT Biopharma will be leading that charge and bringing to the clinic innovative and formidable new NK cell-engager based therapies.”

The company hopes that the new platforms will facilitate faster adoption of the NK cell field’s principles. As per the CEO, combating contemporary illnesses require groundbreaking innovations.

https://factsaboutcbd.org/2018/09/24/gt-biopharma-inc-otcmktsgtbp-makes-great-strides-in-war-against-cancer/